FM December 2020 digital P

THE VACCINE
PROMISE
Excitement builds up as a vaccine
shot to prevent the deadly SARS-
CoV-2 infection becomes real
Following the release of early data from
phase III trials on 9 November, vaccine
makers Pfizer and BioNTech are seeking
regulatory permission to commercialise
their vaccine under emergency-use
authorisation. Moderna, which has also
released early clinical trial data showing
that its vaccine is nearly 95% effective, is
in the process of filing for EUA. Countries
like UK are already set off the registration
procedures to make the vaccine available to
the health care staff at the earliest.
None of these vaccine data, however, has
yet been peer-reviewed.
MODERNA
Vaccine type: messenger RNA
Efficacy: 94%
(spurs immune response
in older adults)
Dosage:
Duration:
Price:
Storage:
Safety:
2 doses
28 days apart
$25 per dose
Remains stable in
conventional refrigerators
for a month and ordinary
freezers for six months
No major adverse drug
event (ADE) reported
during trials
PFIZER/BIONTECH
Vaccine type: messenger RNA
Efficacy:
92%
Dosage:
Duration:
Price:
Storage:
Safety:
2 doses
28 days apart
$15 per dose
−70 °C before delivery
No major ADE reported
during trials
24 / FUTURE MEDICINE / December 2020